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Sotrastaurin, a selective protein-kinase-C inhibitor,
blocks early T-cell activation through a calcineurin-
independent mechanism. In this study, de novo
renal transplant recipients with immediate graft func-
tion were randomized 1:2 to tacrolimus (control,
n = 44) or sotrastaurin (300 mg b.i.d.; n = 81).
All patients received basiliximab, mycophenolic acid
(MPA) and steroids. The primary endpoint was the
composite of treated biopsy-proven acute rejection
(BPAR), graft loss, death or lost to follow-up at
month 3. The main safety assessment was estimated
glomerular filtration rate (eGFR); modification of diet
in renal disease (MDRD) at month 3. Composite effi-
cacy failure at month 3 was higher for the sotrastaurin
versus control regimen (25.7% vs. 4.5%, p = 0.001),
driven by higher BPAR rates (23.6% vs. 4.5%, p =
0.003), which led to early study termination. Median
(± standard deviation [SD]) eGFR was higher for so-
trastaurin versus control at all timepoints from day
7 (month 3: 59.0 ± 22.3 vs. 49.5 ± 17.7 mL/min/1.73
m2, p = 0.006). The most common adverse events
were gastrointestinal disorders (control: 63.6%; so-
trastaurin: 88.9%) which led to study-medication dis-
continuation in two sotrastaurin patients. This study
demonstrated a lower degree of efficacy but better
renal function with the calcineurin-inhibitor-free regi-
men of sotrastaurin+MPA versus the tacrolimus-based
control. Ongoing studies are evaluating alternative so-
trastaurin regimens.
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Introduction
Although acute rejection rates following kidney transplan-
tation have declined in recent years (1), current immuno-
suppressive agents have significant safety and tolerability
shortcomings that hinder successful long-term outcomes
in many patients. Calcineurin inhibitors (CNIs), the corner-
stone of immunosuppression due to their efficacy, are
nephrotoxic, neurotoxic and associated with an increased
risk of cardiovascular events due to their diabetogenic
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potential and increased risk of hypertension and dyslipi-
demia (2). Mycophenolic acid (MPA) is a valuable option
for multidrug immunosuppressive regimens, but its effi-
cacy in preventing acute rejection episodes is insufficient
to avoid using CNIs in de novo patients (3,4). MPA also has
side effects (including an increased risk of hematologic tox-
icity) that are partly due to its antiproliferative actions (5).
Furthermore, the high-intensity immunosuppression pro-
vided by tacrolimus and MPA is associated with an in-
creased risk of polyoma virus-associated nephropathy (6).
CNI-free regimens based on a combination of MPA +
mammalian target of rapamycin (mTOR) inhibitors
(sirolimus/everolimus) appear to improve renal function in
maintenance patients (7,8). However, in de novo renal
recipients they have insufficient efficacy (9) and, for
converted maintenance patients, the risk of protein-
uria may increase (10). Recently, the pivotal pro-
gram for belatacept demonstrated improved glomerular
filtration rate (GFR) but significantly inferior effi-
cacy versus cyclosporine. Hence, the need for new
immunosuppressants with novel mechanisms of action,
particularly calcineurin-independent mechanisms for block-
ing early T-cell activation, remains.
Protein kinase C (PKC) isoforms play key roles in T- and
B-cell signaling (11–13) and therefore represent attrac-
tive therapeutic targets. Sotrastaurin is a small-molecular-
weight immunosuppressant that blocks early T-cell
activation through selective inhibition of PKCh and PKCa,
isoforms that are crucial for IL-2 (14) and interferon-gamma
production (15), respectively. Sotrastaurin markedly pro-
longed graft survival times in experimental heart and
kidney allotransplantation animal models both as
monotherapy and in combination with other immuno-
suppressants (16–19). Preclinical and early clinical studies
demonstrated no signs of nephrotoxicity, hepatotoxicity,
or metabolic or blood-pressure effects at standard expo-
sures (data on file; Novartis Pharma AG, Basel, Switzerland;
2004). Gastrointestinal effects were the dose-limiting toxi-
city in all species tested (data on file; Novartis Pharma AG,
Basel, Switzerland; 2004). Initial concerns regarding the po-
tential for QT-prolongation from in vitro tests (data on file;
Novartis Pharma AG, Basel, Switzerland; 2004) have not
been confirmed at therapeutic doses in healthy-volunteer
studies (20), a thorough QT study (data on file; Novartis
Pharma AG, Basel, Switzerland; 2009) or in clinical studies
to date (21). A reversible increase in mean ventricular heart
rate (HR) was observed following a single 500 mg dose of
sotrastaurin with mean HRs in the upper part of the normal
range in healthy-volunteer studies (20).
In six patients with moderate-to-severe plaque psoriasis,
sotrastaurin (300 mg b.i.d.) resulted in a mean reduction
from baseline of 69% for the Psoriasis Area and Severity
Index score after 2 weeks’ treatment (20), which is com-
parable to the efficacy observed with cyclosporine (22).
Since psoriasis is a T-cell-mediated disease, the efficacy of
sotrastaurin in this setting may predict its immunosuppres-
sive activity in transplant recipients.
Because sotrastaurin blocks early T-cell activation through
a calcineurin-independent mechanism, and based on en-
couraging results in animal models (19), it was tested
in CNI-free immunosuppressive regimens in combina-
tion with current adjunctive therapies such as MPA and
mTOR inhibitors. This phase II study evaluated the ef-
ficacy, safety and tolerability of oral sotrastaurin+MPA




This study (ClinicalTrials.gov: NCT00492869) was designed as a 12-month,
open-label, randomized, dose-finding, two-stage study. It was conducted
between June 2007 and May 2008 in 26 centers in Europe, North America
and Asia.
Male and female patients aged ≥18 years who were recipients of a primary
kidney transplant from a deceased, living unrelated or non-HLA-identical
living-related donor were eligible. Patients had to receive a kidney with a
cold ischemic time (CIT) <24 h from a donor aged 10–65 years, and have
a functional graft within 24 h after graft reperfusion (defined as urine out-
put >250 mL/12 h for patients without residual urinary output from the
native kidneys or a decrease in serum creatinine by ≥20% from pretrans-
plant level). Important exclusion criteria included: multiorgan transplant
recipients or patients who had previously received an organ transplant,
recipients of an organ from a non-heart-beating donor, recipients of ABO-
incompatible or cross-match-positive transplants, and patients with a sig-
nificant cardiac history (e.g. long QT-syndrome; unstable angina, recent
hospitalization for heart failure or significant and persistent left ventricular
dysfunction during the previous 6 months). All patients gave written, in-
formed consent and the study was conducted in accordance with the Inter-
national Conference on Harmonized Tripartite Guidelines for Good Clinical
Practice and local regulations and was reviewed by the Independent Ethics
Committee/Institutional Review Board for each center. An independent
data-monitoring committee (DMC) was established at study commence-
ment.
All patients were scheduled to receive one dose of basiliximab 20 mg
and MPA 720 mg prior to transplantation. If the graft showed immediate
function, patients were randomized (stratified by donor source and center)
within 24 h of transplant in a 1:2 ratio to receive either tacrolimus (initial
dose 0.1mg/kg b.i.d., target trough levels: month 1: 8–15 ng/mL; month 2–
3: 6–12 ng/mL; month 4–12: 5–10 ng/mL; control regimen) or sotrastaurin
300 mg b.i.d. (sotrastaurin regimen). The randomization list was produced
by the study sponsor using a validated system that automated the random
assignment of treatment arms to randomization numbers in the specified
ratio. Each center received a set of treatment allocation cards on which the
treatment group information was covered by a scratch-off label. Patients
were given the lowest numbered card available; the scratch-off labels were
then removed revealing designated treatment. All patients received a sec-
ond 20 mg basiliximab dose on day 4 post-transplant and MPA 720 mg
b.i.d. for study duration. The initial dose of corticosteroids was 500 mg at
transplantation, 250 mg on day 2, 125 mg on day 3 and 0.5 mg/kg from day
4, tapered to 5–10 mg/day by month 1 and to ≥5 mg/day at day 45 until
month 12.
Acute rejections were treated with steroids according to local practice.
Patients were discontinued and converted to local standard of care if they
experienced a rejection requiring the use of other antirejection therapy (i.e.
antibodies), a biopsy-proven acute rejection (BPAR) Banff grade ≥2, more
than one BPAR of any grade, or more than one treated acute rejection.
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Efficacy and safety assessments were scheduled on days 1, 2, 3, 4, 8,
15 and 22, and then monthly for months 1–12. Patients who prematurely
discontinued study drug remained in the study and were scheduled to
undergo follow-up visits at months 3, 6 and 12.
Efficacy assessments
The primary efficacy endpoint was the composite of treated BPAR, graft
loss, death or lost to follow-up at month 3 (day 104). Secondary efficacy
variables included analyses of the components of the primary variable.
A graft core biopsy was to be performed within 48 h of all suspected
rejection episodes, regardless of antirejection treatment. Biopsies were
graded by the local pathologist using 2003 Banff criteria (23). A BPAR
was defined as a clinically apparent rejection episode confirmed by a
biopsy graded Banff IA or greater, or antibody-mediated rejection (AMR)
treated with antirejection therapy. BPARs were treated according to local
practice.
Safety assessments
The main safety assessment was renal function estimated by GFR (eGFR)
using the abbreviated modification of diet in renal disease (MDRD) formula
(24) at months 3 and 12. Other safety assessments included adverse events
(AEs), discontinuations, hematology, standard laboratory measures, vital
signs, electrocardiograms (ECGs) and physical examinations.
Statistical methods
Patient background information was summarized using descriptive statis-
tics (n, mean, median, standard deviation [SD], minimum and maximum)
for continuous variables and frequency distributions (percentages) for cat-
egorical variables. All efficacy analyses were based on the intent-to-treat
analysis set, comprising all randomized patients. The safety analyses were
performed on the same analysis set as all randomized patients were treated
with the randomized study medication. The primary endpoint was evaluated
for noninferiority by computing a Z-test-based 95% confidence interval to
determine the difference in efficacy-failure probabilities for the sotrastau-
rin versus the control regimen. Efficacy-failure probabilities were obtained
from Kaplan–Meier estimates considering efficacy events up to 7 days af-
ter discontinuation of study medication (on-treatment). The median eGFRs
between treatment regimens were compared using a two-sided Wilcoxon
rank sum test. No multiplicity adjustment was made for multiple treatment
comparisons because the analyses were not of a confirmatory nature. No
missing-data imputation was performed.
Sample size and power considerations
The study was designed to assess efficacy-failure rates for the sotrastaurin
versus control arm. A sample size of 129 (sotrastaurin: n = 86; control:
n = 43) was required to demonstrate that the upper bound of the two-
sided 95% confidence interval for the difference in primary efficacy-failure
rates (sotrastaurin-control arm) was ≤20% at month 3. A failure rate of 12%
in both arms would have led to a power of approximately 90%. The margin
of 20% was selected because the data were to be used for feasibility
assessment and decision making about starting the dose-ranging second
stage of the study, rather than hypothesis testing.
Results
Patients
A total of 125 patients were randomized (control: n =
44; sotrastaurin: n = 81; Figure 1). Both groups consisted
predominantly of Caucasian patients (control: 90.9% and
sotrastaurin: 82.7%) and were well matched for base-
line characteristics, except that the control group included
more males (72.7%, 32/44) than the sotrastaurin group
(60.5%, 49/81; Table 1). Median follow-up times were 147
days for control and 120 for sotrastaurin.
Immunosuppressant dosing
Patients were exposed to study drug for a median dura-
tion of 110 (range: 2–228) versus 75 (range: 1–240) days
with the control and sotrastaurin regimens, respectively.
Median sotrastaurin trough levels remained between 604
and 807 ng/mL during the study. In the control group, the
majority of patients were within the protocol-defined
trough tacrolimus target ranges throughout the study, with
median trough levels between 7.9 and 11.0 ng/mL. The
control and sotrastaurin groups had similar mean daily MPA
doses of 1361 and 1302 mg/day at month 1, and 1294 and
1211 mg/day at month 3, respectively. Median MPA trough
levels at month 1 were 3613 ng/mL and 3160 ng/mL with
the sotrastaurin and control regimens, respectively, and
4720 ng/mL and 3560 ng/mL at month 3. Both groups had
mean oral steroid doses of 0.2 mg/kg at month 1 and 0.1
mg/kg at month 3.
Efficacy
During the first 4 weeks post-transplant, composite-
endpoint rates were similar between treatment regimens.
Beyond this, the event curves for the two regimens di-
verged, due to BPARs with the sotrastaurin regimen
(Figure 2). By month 3, a higher proportion of sotrastaurin-
regimen versus control-regimen patients had experienced
primary efficacy failure (25.7% [n = 16] vs. 4.5% [n =
2]; p = 0.001; Table 2) and the study was terminated
based on the DMC’s recommendation. All patients were
discontinued from study medication and converted to lo-
cal standard-of-care treatment. Month-6, post hoc Kaplan–
Meier estimates of efficacy endpoints are presented in
Table 3.
At the time of study termination, 17 patients had expe-
rienced BPARs with the sotrastaurin regimen, including
three patients who had their first BPAR after month 3.
Banff grades of these 17 patients (most severe is stated
where patients experienced more than one BPAR) were
as follows: IA (one patient), IB (five), IIA (nine) and IIB
(two). Complete resolution occurred in 10 patients, while 5
had residual renal dysfunction and 2 had no improvement.
Ultimately, one patient with no improvement lost her graft
3 months after conversion to a different regimen, in a
context of recurring and unresponsive rejection; histologi-
cally, signs of AMR became apparent 2 months after con-
version. No other patient showed signs of AMR. One addi-
tional patient experienced a IB BPAR 12 days after discon-
tinuation of study medication (off-treatment), which was
therefore not considered in the primary analysis according
to the prespecified rules. Two control-regimen patients ex-
perienced BPARs, one Banff IB (the outcome was residual
renal dysfunction) and the other IIB (which resolved).
Other variables included in the composite endpoint were
graft loss and death. Neither group had any graft losses
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Figure 1: Flow of patients through the study.
∗Patients could have ≥1 reason for screening failure, †includes two patients whose adverse event was acute rejection. Control regimen:
tacrolimus + MPA; sotrastaurin regimen: sotrastaurin + MPA; ITT: intent-to-treat; MPA: mycophenolic acid.
but on day 27 post-transplant, one sotrastaurin-regimen
patient died 1 day after discharge from wound-revision
surgery. The clinical context suggests pulmonary em-
bolism but no autopsy was performed. The cause of death
was reported as a cardiac arrest and was not suspected
by the investigator to be related to study drug. No control-
regimen patients died during the study. At last observa-
tion, one sotrastaurin-regimen patient had died and one
had lost their graft; no control-regimen patients had either
died or lost their graft. One control-regimen patient and
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Table 1: Baseline demographics and characteristics of donors and recipients
Control N = 44 Sotrastaurin N = 81
Recipient
Mean age, years (range) 48.3 (20–72) 46.4 (20–70)
Male, n (%) 32 (72.7) 49 (60.5)
Race, n (%)
Caucasian 40 (90.9) 67 (82.7)
Black 2 (4.5) 5 (6.2)
Asian 1 (2.3) 5 (6.2)
Other 1 (2.3) 4 (4.9)
End-stage renal disease leading to transplant, n (%)
Glomerular disease 10 (22.7) 20 (24.7)
Diabetes mellitus 7 (15.9) 6 (7.4)
Polycystic disease 5 (11.4) 13 (16.0)
Hypertension/nephrosclerosis 4 (9.1) 9 (11.1)
Unknown 3 (6.8) 7 (8.6)
Other 15 (34.1) 26 (32.1)
Pre-emptive transplantation, n (%) 10 (22.7) 18 (22.2)
Panel reactive antibodies >5%, n (%) 6 (13.6) 3 (3.7)
Number of HLA matches, mean (SD) 3.2 (2.0) 3.4 (1.7)
Zero HLA mismatches, n (%) 12 (27.3) 13 (16.0)
Cold ischemic time in hours, median (range)∗ 13.5 (4.8–22.8) 15.4 (5.2–25.3)
Donor
Living related, n (%) 15 (34.1) 23 (28.4)
Living unrelated, n (%) 8 (18.2) 20 (24.7)
Deceased, n (%) 21 (47.7) 38 (46.9)
Donor
Mean age, years (range) 43.5 (17.0–62.0) 42.7 (16.0–65.0)
Male, n (%) 16 (36.4) 48 (59.3)
∗For deceased, heart-beating donors only.
Control regimen: tacrolimus + MPA; sotrastaurin regimen: sotrastaurin + MPA.
HLA = human leukocyte antigen; MPA = mycophenolic acid; SD = standard deviation.
three sotrastaurin-regimen patients withdrew consent dur-
ing the study.
To explore exposure–efficacy associations for sotrastau-
rin, a time-weighted average trough level until month 3
or event was calculated for each patient, and patients
were sorted to trough-level tertiles. In the lowest tertile,
27% of patients experienced a BPAR, versus 12% in the
highest tertile. However, no reliable sotrastaurin thera-
peutic trough-level range for efficacy could be identified
(Figure 3).
Safety
Renal function: Renal function assessed by eGFR (MDRD;
Figure 4) and serum creatinine was significantly improved
Figure 2: Kaplan–Meier plot
of time to first on-treatment
composite primary efficacy
failure. Note that a Kaplan–
Meier analysis is used to
present the primary efficacy
endpoint in line with the protocol
although the study was termi-
nated early. Control regimen:
tacrolimus + MPA; sotrastaurin
regimen: sotrastaurin + MPA.
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Table 2: Kaplan–Meier estimates of efficacy endpoints at 3 months∗
Control Sotrastaurin 95% CI of Difference in K–M
N = 44, n (%) N = 81, n (%) difference (%) estimate (p-Value)
Composite efficacy failure 2 (4.5) 16 (25.7) (8.4, 34.0) 0.001
Treated BPAR 2 (4.5) 14 (23.6) (6.4, 31.8) 0.003
Graft loss 0 0 – –
Death 0 1 (1.4) (−1.4, 4.3) 0.314
Lost to follow-up 0 1 (1.2) (−1.2, 3.6) 0.314
BPAR = biopsy-proven acute rejection; CI = confidence interval; K–M = Kaplan–Meier.
Control regimen: tacrolimus + MPA; sotrastaurin regimen: sotrastaurin + MPA.
Composite efficacy failure: treated BPAR, death, graft loss, lost to follow-up; treated BPAR: clinical signs of acute rejection (confirmed by
biopsy showing Banff ≥IA) and antirejection therapy given.
∗Day 104 or events (except lost to follow-up) within 7 days of discontinuation of study drug were used as the cut-off for this analysis.
†Day 180 or events (except lost to follow-up) within 7 days of discontinuation of study drug were used as the cut-off for this post hoc
analysis.
with the sotrastaurin versus the control regimen in both
all-data and on-treatment analyses. The improvements
in calculated creatinine clearance achieved with the so-
trastaurin regimen did not reach statistical significance
(Table 4). The differences in renal-function parameters
were noted as early as postoperative day 4, achieved sta-
tistical significance at week 2, and remained significant
until month 6. Of note, the benefit in eGFR with the
Table 3: Kaplan–Meier estimates of efficacy endpoints at 6 months†
Control Sotrastaurin 95% CI of Difference in K–M
N = 44, n (%) N = 81, n (%) difference n (%) estimate (p-Value)
Composite efficacy failure 2 (4.5) 19 (34.9) (15.0, 45.7) <0.001
Treated BPAR 2 (4.5) 17 (33.1) (13.0, 44.0) <0.001
Graft loss 0 0 – –
Death 0 1 (1.4) (−1.4, 4.3) 0.314
Lost to follow-up 0 1 (1.2) (−1.2, 3.6) 0.314
BPAR = biopsy-proven acute rejection; CI = confidence interval; K–M = Kaplan–Meier.
Control regimen: tacrolimus + MPA; sotrastaurin regimen: sotrastaurin + MPA.
Composite efficacy failure: treated BPAR, death, graft loss, lost to follow-up; treated BPAR: clinical signs of acute rejection (confirmed by
biopsy showing Banff ≥IA) and antirejection therapy given.
∗Day 104 or events (except lost to follow-up) within 7 days of discontinuation of study drug were used as the cut-off for this analysis.
†Day 180 or events (except lost to follow-up) within 7 days of discontinuation of study drug were used as the cut-off for this post hoc
analysis.
Figure 3: Exposure–efficacy analy-
ses of sotrastaurin trough levels by
biopsy-proven acute rejection and
composite endpoint status. BPAR+:
patients experiencing biopsy-proven
acute rejection; BPAR−: patients not
experiencing biopsy-proven acute
rejection; composite endpoint+: pa-
tients experiencing any component of
composite endpoint; composite
endpoint−: patients not experienc-
ing any component of composite
endpoint.
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Figure 4: Median (±SE) estimated glomerular filtration rate by modification of diet in renal disease equation for safety analysis
set. All data are included in this figure, i.e. including those collected after study-medication discontinuation. SE = nonparametric standard
error = interquartile range/(1.075 ∗ sqrt[n]); eGFR = estimated glomerular filtration rate; MDRD = modification of diet in renal disease
formula.
sotrastaurin regimen remained even when patients who
had experienced rejections and been converted to the lo-
cal standard-of-care regimen were included in the analy-
sis. Median (range) GFR for patients experiencing rejec-
tion at month 3 for whom data were available (n = 17) was
45 (18–95) mL/min/1.73 m2. The low patient numbers be-
yond month 6 precluded meaningful analysis for later time
points.
Table 4: Renal function at 3 and 6 months
Control Sotrastaurin p-Value
At 3 months
All data, median ± SD N = 36 N = 61
eGFR (MDRD) in mL/min/1.73 m2 49.5 ± 17.7 59.0 ± 22.3∗ 0.006
Calculated creatinine clearance (Cockcroft–Gault) in mL/min 64.5 ± 20.5 75.5 ± 27.9∗ 0.080
Serum creatinine in lmol/L 137.5 ± 45.6 106.0 ± 27.0 < 0.001
On-treatment, median ± SD N = 29 N = 38
eGFR (MDRD) in mL/min/1.73 m2 49.0 ± 14.9 59.0 ± 29.8† 0.040
Calculated creatinine clearance (Cockcroft–Gault) in mL/min 64.0 ± 17.7 74.0 ± 26.0 0.068
Serum creatinine in lmol/L 137.0 ± 41.9 103.5 ± 31.6 0.003
At 6 months
All data, median ± SD N = 23 N = 33
eGFR (MDRD) in mL/min/1.73 m2 52.0 ± 11.2 59.0 ± 26.0 0.180
Calculated creatinine clearance (Cockcroft–Gault) in mL/min 66.5 ± 14.9‡ 68.0 ± 28.8 0.700
Serum creatinine in lmol/L 129.0 ± 26.0 109.0 ± 27.9 0.046
On-treatment, median ± SD N = 14 N = 17
eGFR (MDRD) in mL/min/1.73 m2 51.0 ± 14.0 54.0 ± 19.1§ 0.371
Calculated creatinine clearance (Cockcroft–Gault) in mL/min 59.0 ± 17.2∗∗ 64.0 ± 26.0 0.912
Serum creatinine in lmol/L 126.0 ± 23.3 106.0 ± 33.5 0.351
eGF = glomerular filtration rate; MDRD = modification of diet in renal disease; SD = nonparametric standard deviation = interquartile
range/1.075.
Control regimen: tacrolimus + MPA; sotrastaurin regimen: sotrastaurin + MPA.
Both analyses were conducted on the intent-to-treat analysis set.
All-data analysis: all reported data were included; on-treatment analysis: data collected more than 2 days after discontinued study
medication were not included.
∗n = 60; †n = 37; ‡n = 20; §n = 16; ∗∗n = 12 (numbers differ owing to availability of data used in formulae).
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Table 5: Incidence of adverse events (AEs) occurring in ≥10%∗ with either regimen
Control N = 44, n (%) Sotrastaurin N = 81, n (%)
At least one AE 43 (97.7) 79 (97.5)
Any SAE 13 (29.5) 38 (46.9)
Adverse events leading to discontinuation of study medication 2 (4.5) 18 (22.2)
Adverse events
Blood and lymphatic system disorders
Anemia 6 (13.6) 16 (19.8)
Cardiac disorders
Tachycardia∗ 2 (4.5) 8 (9.9)
Gastrointestinal disorders
Constipation 10 (22.7) 46 (56.8)
Diarrhea 14 (31.8) 33 (40.7)
Nausea 8 (18.2) 35 (43.2)
Vomiting 6 (13.6) 25 (30.9)
General disorders and administration site conditions
Peripheral edema 9 (20.5) 12 (14.8)
Infections and infestations
Urinary tract infection 10 (22.7) 16 (19.8)
Injury, poisoning and procedural complications
Procedural pain 9 (20.5) 16 (19.8)
Investigations
Increased blood creatinine 8 (18.2) 8 (9.9)
Metabolism and nutrition disorders
Hyperglycemia 4 (9.1) 10 (12.3)
Hyperkalemia 6 (13.6) 7 (8.6)
Hypocalcemia 3 (6.8) 9 (11.1)
Hypokalemia 5 (11.4) 10 (12.3)
Hypomagnesemia 11 (25.0) 7 (8.6)
Hypophosphatemia 9 (20.5) 12 (14.8)
Musculoskeletal and connective tissue disorders
Arthralgia 5 (11.4) 3 (3.7)
Nervous system disorders
Dizziness 5 (11.4) 12 (14.8)
Dysgeusia 0 11 (13.6)
Headache 7 (15.9) 5 (6.2)
Tremor 9 (20.5) 6 (7.4)
Psychiatric disorders
Insomnia 7 (15.9) 21 (25.9)
Renal and urinary disorders
Dysuria 6 (13.6) 8 (9.9)
Vascular disorders
Hypotension 5 (11.4) 6 (7.4)
∗Tachycardia is included although the incidence was <10% with both treatment regimens as it was considered an important finding.
Adverse events: With both regimens, most patients ex-
perienced at least one AE (Table 5), the majority being
mild-to-moderate in severity. The most frequent AEs
were gastrointestinal disorders (control: 63.6%, 28/44;
sotrastaurin: 88.9%, 72/81) and metabolism and
nutrition disorders (control: 61.4%, 27/44; sotrastaurin:
59.3%, 48/81). Serious adverse events (SAEs) were re-
ported in 29.5% (13/44) and 46.9% (38/81) of patients
receiving the control and sotrastaurin regimen, respec-
tively. SAEs were most frequently related to infections
(three and nine patients, respectively) or hospitaliza-
tions secondary to an acute rejection. The majority of
infections were a secondary complication of another AE
such as wound dehiscence/infection, and duodenal ul-
cer perforation. Bacteria were identified as the cause for
seven of the nine infection SAEs with the sotrastaurin reg-
imen. AEs leading to study-drug discontinuation occurred
in 4.5% (2/44) of patients receiving the control and 22.2%
(18/81) receiving the sotrastaurin regimen. Half of the dis-
continuations with each regimen were a result of acute
rejection.
Gastrointestinal adverse events
Constipation, diarrhea, nausea and vomiting were the most
commonly reported gastrointestinal AEs for both regimens
and occurred at a higher frequency with the sotrastaurin
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versus the control regimen (Table 5). The majority of gas-
trointestinal AEs were single events, and were rated by the
investigator as mild; two cases of diarrhea and one of nau-
sea were rated as severe with the sotrastaurin regimen.
Twenty-one gastrointestinal-related AEs required dosage
adjustment/interruption with the sotrastaurin versus four
with the control regimen. Two gastrointestinal AEs (nau-
sea and intestinal perforation) required permanent study-
drug discontinuation or hospitalization with the sotrastaurin
regimen.
Dysgeusia: Dysgeusia was only reported with the so-
trastaurin regimen (13.6%, 11/81). It was described as a
bad or metallic taste, usually mild and reported by week 3.
One event required a study-drug dosage adjustment.
Cardiac effects: The overall incidence of cardiac AEs was
higher with the sotrastaurin (22.2%, 18/81) versus the con-
trol regimen (13.6%, 6/44). The only cardiac AE with an in-
cidence >5% was tachycardia, which was reported more
frequently with the sotrastaurin (9.9%, 8/81) versus the
control regimen (4.5%, 2/44) (Table 5). Both tachycardia
AEs in control patients and six of those in sotrastaurin-
regimen patients occurred by week 3. All were rated as
mild by the investigator and were managed with either
concomitant medication or nondrug therapy, or no action
was taken. The sotrastaurin regimen was associated with
a numerically higher incidence of ECG-measured tachycar-
dia (>25% increase in HR from baseline resulting in a HR
of >100 beats per minute [bpm] at any time during the
study) versus control (27.5%, 22/80 vs. 14.6%, 6/41; 95%
confidence interval: −1.7, 27.5; calculated using data only
from patients who had a measurement at baseline and
any time postbaseline). No significant differences in the
PR, QRS or QT intervals from centrally read ECGs were
observed between the regimens (data not shown).
Diabetes: Diabetes mellitus AEs were reported more
often in patients receiving the control (6.8%, 3/44) versus
the sotrastaurin regimen (2.5%, 2/81). In addition, glycated
hemoglobin elevation (>6.4%) occurred more frequently
with control versus the sotrastaurin regimen (27.3%, 12/44
vs. 11.3%, 8/71, respectively) as did high blood glucose
(>13.9 mmol/L: 15.9%, 7/44 vs. 7.4%, 6/81, respectively).
Conversely, hyperglycemia was reported more frequently
as an AE with the sotrastaurin regimen than with control
(12.3%, 10/81 vs. 9.1%, 4/44, respectively; Table 5).
Infections: The incidence of infections was similar for
the two regimens (Table 6). Urinary tract infection was
the most frequent infection reported (control: 22.7%,
10/44; sotrastaurin: 19.8%, 16/81). Bacterial infections
were the most frequent type occurring in 20.5% (9/44)
and 29.6% (24/81) of patients receiving the control and so-
trastaurin regimens, respectively. No patients developed
cytomegalovirus (CMV) infection and both regimens had
similar incidences of patients with BK-polyoma viremia,
defined as a viral load >103 copies/mL, while on treatment
Table 6: Incidence of infections
Control Sotrastaurin
N = 44, n (%) N = 81, n (%)
Infections
Any infection 21 (47.7) 37 (45.7)
Any serious infection 3 (6.8) 9 (11.1)
Bacterial 9 (20.5) 24 (29.6)
Viral 2 (4.5) 4 (4.9)
Fungal 2 (4.5) 5 (6.2)
Unknown 14 (31.8) 20 (24.7)
Control regimen: tacrolimus + MPA; sotrastaurin regimen: so-
trastaurin + MPA.
MPA = mycophenolic acid; SAE = serious adverse event.
(control: 6.8%, 3/44; sotrastaurin: 6.2%, 5/81). Histologi-
cal signs of BK nephropathy were observed in one patient
receiving the sotrastaurin regimen, and one after discon-
tinuation of study therapy.
It was impossible to determine whether a relationship ex-
isted between sotrastaurin trough levels and tolerability
because of limited follow-up and the confounding effect of
MPA (data not shown).
Discussion
Sotrastaurin blocks PKC-mediated early T-cell activation
(20) providing a new approach for immunosuppression
distinct from calcineurin inhibition. However, the efficacy
results of this phase II study do not support the com-
bination of sotrastaurin 300 mg b.i.d. + MPA as a CNI-
free regimen. Despite showing comparable efficacy to the
tacrolimus+MPA control regimen during the first 4 weeks
after transplantation, efficacy of the CNI-free sotrastaurin
regimen subsequently diminished. Although higher acute
rejection rates may be an acceptable trade-off for improved
renal function, and the observed rejections on treatment all
appeared to be T-cell mediated, the improvements in renal
function in patients randomized to the sotrastaurin+MPA
regimen versus the control regimen in this study were con-
sidered insufficient to outweigh the higher acute rejection
rate. The acute rejection rate was deemed unacceptably
high and the study was terminated.
Several factors may have contributed to the inadequate
efficacy associated with the sotrastaurin+MPA combina-
tion. Although the present study did not show a clear as-
sociation between efficacy failure and exposure, patients
with efficacy failure had a numerically lower sotrastau-
rin trough level. In theory, the immunosuppressive effi-
cacy might be improved by increasing exposure levels, but
this appears to be unfeasible for the sotrastaurin+MPA
regimen due to dose-limiting gastrointestinal AEs. Re-
ducing MPA exposure might reduce gastrointestinal side
effects but this is unfeasible due to lack of efficacy
with this regimen; combining sotrastaurin with other
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immunosuppressants might improve gastrointestinal tol-
erability. No pharmacokinetic drug–drug interactions exist
between sotrastaurin and MPA (25); therefore, efficacy fail-
ure from insufficient MPA exposure is unlikely.
The efficacy of CNIs demonstrates that early T-cell-
activation inhibition is a key to immunosuppressive ef-
fectiveness; however, the long-term side effects of CNIs
(cardiovascular events, nephrotoxicity, and neurotoxicity)
(2) highlight the need for alternative methods of inhibit-
ing early T-cell activation. While the use of an mTOR
inhibitor+MPA regimen in the maintenance period appears
to be feasible (7), de novo CNI-free immunosuppression is
invariably associated with an increase in rejection rate (26).
Similarly, the first large-scale study assessing CNI-free im-
munosuppression using intravenous costimulatory block-
ade demonstrated higher acute rejection rates in the be-
latacept versus the CNI arms (22% and 17% vs. 7% for the
more-intensive-belatacept, less-intensive-belatacept and
cyclosporine regimens, respectively) (27). Although the
combination of sotrastaurin and MPA demonstrated insuffi-
cient efficacy in this study, CNI side effects were absent. As
early as postoperative day 4, better renal function was ob-
served in patients randomized to sotrastaurin+MPA versus
the control regimen. Other expected benefits of a CNI-free
regimen included a reduced incidence of HbA1c elevation
and high blood glucose levels, and a decreased incidence
of tremor.
No significant safety concerns were documented with so-
trastaurin in combination with MPA. Dysgeusia was gen-
erally mild, required no action by the investigator, and
did not lead to discontinuation of sotrastaurin. Nausea,
vomiting, constipation and diarrhea were the most com-
monly reported AEs with both regimens. Gastrointestinal
AEs occurred more frequently with the sotrastaurin+MPA
regimen, which was consistent with data from previ-
ous healthy-volunteer and psoriasis studies at sotrastaurin
doses of >200 mg b.i.d. (20). The majority of gastroin-
testinal AEs were rated as mild but more required dose
adjustment or interruption with the sotrastaurin versus the
control regimen. It was not possible to draw conclusions
about the relationship between sotrastaurin concentration
and tolerability because of limited follow-up and the con-
founding effect of MPA.
Neither regimen showed signs of severe overimmuno-
suppression and the infections reported were typical
of organ transplant recipients. Many of the infections
were secondary to other conditions (e.g. sepsis follow-
ing duodenal-ulcer perforation). BK-polyoma nephropathy
and CMV infection were not observed, possibly due
to the use of CMV prophylaxis and the short study
duration.
A dose-dependent chronotropic effect has been observed
in preclinical and phase I sotrastaurin studies (20); there-
fore the higher HR and tachycardia AEs observed with
the sotrastaurin+MPA regimen were not unexpected.
All tachycardia AEs were mild and managed conserva-
tively, and the majority occurred soon after transplantation.
Although an in vitro preclinical study suggested a poten-
tial for QT prolongation, no QT effect was observed in this
study.
When interpreting the results, it should be considered that
the majority of patients were Caucasian, the proportion
with diabetes or hypertension as the cause of end-stage
renal disease requiring transplantation was low and pa-
tients were immunologically low risk (recipients of a first
transplant with CIT <24 h; exclusion of patients with de-
layed graft function or receiving a donor organ from a
donor aged >65 years). In addition, the relatively small
sample size, an unblinded protocol, multiple participating
centers, local evaluation of renal biopsies and a relatively
short follow-up due to the premature cessation of the trial
might have had a negative impact on our ability to precisely
determine the incidence and severity of biopsy-proven
acute rejection episodes. These shortcomings are in part
intrinsic to the nature of a phase II study whose main ob-
jective was to determine whether the sotrastaurin+MPA
drug regimen should be further developed in larger clinical
trials.
In conclusion, the CNI-free sotrastaurin+MPA regimen
was associated with increased rejection rates from week
4 onwards. However, this regimen showed an acceptable
safety profile, and evidence of potential benefits includ-
ing improved renal function versus the control. These re-
sults indicate that further characterization of sotrastaurin as
a component of multidrug immunosuppressive regimens
that exploit its calcineurin-independent mechanism for in-
hibiting early T-cell activation is warranted. Studies evaluat-
ing the efficacy and safety of other sotrastaurin regimens,
including dose-ranging studies combining sotrastaurin with
both everolimus and tacrolimus, are ongoing and planned.
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